Quote:

---

So, when a certain patent does come to an end in about 50+ days, can we expect some companies to begin incorporating leronlimab into their technology and if so, the development of some revenue for CytoDyn?

---

The general patent that is of importance is the concentrated formulation of leronlimab that expires in 2031. You would have to pump in huge amounts of the non-concentrated formulation to get a high level of CCR5 coverage. Of course then you have 12 years of FDA exclusivity on first approval followed by specific disease patents.